Sagent Pharmaceuticals (SGNT)

16.28 +0.34  +2.13%  May 17, 8:00PM
Add to Watchlists Create an Alert

Sagent Pharmaceuticals R&D Expense Quarterly:

4.261M for March 31, 2013
View Full Chart

Sagent Pharmaceuticals R&D Expense Quarterly Chart

    Sagent Pharmaceuticals Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 4.261M
    Dec. 31, 2012 4.436M
    Sept. 30, 2012 4.011M
    June 30, 2012 4.058M
    March 31, 2012 4.631M
    Dec. 31, 2011 4.572M
    Sept. 30, 2011 3.46M
       
    June 30, 2011 2.374M
    March 31, 2011 2.357M
    Dec. 31, 2010 2.623M
    Sept. 30, 2010 2.534M
    June 30, 2010 3.272M
    March 31, 2010 2.794M
    Dec. 31, 2009 2.493M

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    SGNT R&D Expense Quarterly Benchmarks

    Companies
    Teva Pharmaceutical Industries 329.00M
    Acura Pharmaceuticals 2.026M
    Horizon Pharma 4.739M

    SGNT R&D Expense Quarterly Rankings

    Overall 88th percentile
    888 of 7593
    Sector 61st percentile
    253 of 650 in Healthcare
    Industry 43rd percentile
    37 of 65 in Drug Manufacturers - Specialty & Generic

    SGNT R&D Expense Quarterly Range, Past 5 Years

    Minimum 2.357M Mar 2011
    Maximum 4.631M Mar 2012
    Average 3.420M